BICYCLE THERAPEUTICS PLC-ADR (BCYC) Fundamental Analysis & Valuation

NASDAQ:BCYC • US0887861088

Current stock price

4.94 USD
-0.03 (-0.6%)
At close:
4.9 USD
-0.04 (-0.81%)
After Hours:

This BCYC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BCYC Profitability Analysis

1.1 Basic Checks

  • BCYC had negative earnings in the past year.
  • In the past year BCYC has reported a negative cash flow from operations.
  • In the past 5 years BCYC always reported negative net income.
  • BCYC had a negative operating cash flow in each of the past 5 years.
BCYC Yearly Net Income VS EBIT VS OCF VS FCFBCYC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • BCYC's Return On Assets of -30.51% is fine compared to the rest of the industry. BCYC outperforms 64.99% of its industry peers.
  • With a decent Return On Equity value of -35.90%, BCYC is doing good in the industry, outperforming 70.60% of the companies in the same industry.
Industry RankSector Rank
ROA -30.51%
ROE -35.9%
ROIC N/A
ROA(3y)-26.17%
ROA(5y)-23.98%
ROE(3y)-35.31%
ROE(5y)-33.37%
ROIC(3y)N/A
ROIC(5y)N/A
BCYC Yearly ROA, ROE, ROICBCYC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCYC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCYC Yearly Profit, Operating, Gross MarginsBCYC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BCYC Health Analysis

2.1 Basic Checks

  • BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BCYC has more shares outstanding
  • The number of shares outstanding for BCYC has been increased compared to 5 years ago.
  • Compared to 1 year ago, BCYC has a worse debt to assets ratio.
BCYC Yearly Shares OutstandingBCYC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BCYC Yearly Total Debt VS Total AssetsBCYC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • BCYC has an Altman-Z score of 0.18. This is a bad value and indicates that BCYC is not financially healthy and even has some risk of bankruptcy.
  • BCYC has a Altman-Z score (0.18) which is in line with its industry peers.
  • BCYC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • BCYC's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. BCYC outperforms 50.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.18
ROIC/WACCN/A
WACC9.32%
BCYC Yearly LT Debt VS Equity VS FCFBCYC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 11.98 indicates that BCYC has no problem at all paying its short term obligations.
  • BCYC has a Current ratio of 11.98. This is amongst the best in the industry. BCYC outperforms 85.30% of its industry peers.
  • A Quick Ratio of 11.98 indicates that BCYC has no problem at all paying its short term obligations.
  • The Quick ratio of BCYC (11.98) is better than 85.30% of its industry peers.
Industry RankSector Rank
Current Ratio 11.98
Quick Ratio 11.98
BCYC Yearly Current Assets VS Current LiabilitesBCYC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BCYC Growth Analysis

3.1 Past

  • The earnings per share for BCYC have decreased by -7.12% in the last year.
  • The Revenue has grown by 105.77% in the past year. This is a very strong growth!
  • Measured over the past years, BCYC shows a very strong growth in Revenue. The Revenue has been growing by 47.52% on average per year.
EPS 1Y (TTM)-7.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.63%
Revenue 1Y (TTM)105.77%
Revenue growth 3Y71.22%
Revenue growth 5Y47.52%
Sales Q2Q%1193.28%

3.2 Future

  • Based on estimates for the next years, BCYC will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.79% on average per year.
  • The Revenue is expected to grow by 77.32% on average over the next years. This is a very strong growth
EPS Next Y-20.36%
EPS Next 2Y-5.36%
EPS Next 3Y6.12%
EPS Next 5Y15.79%
Revenue Next Year5.39%
Revenue Next 2Y-14.06%
Revenue Next 3Y45.31%
Revenue Next 5Y77.32%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCYC Yearly Revenue VS EstimatesBCYC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
BCYC Yearly EPS VS EstimatesBCYC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. BCYC Valuation Analysis

4.1 Price/Earnings Ratio

  • BCYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BCYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCYC Price Earnings VS Forward Price EarningsBCYC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCYC Per share dataBCYC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.36%
EPS Next 3Y6.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCYC Dividend Analysis

5.1 Amount

  • BCYC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCYC Fundamentals: All Metrics, Ratios and Statistics

BICYCLE THERAPEUTICS PLC-ADR

NASDAQ:BCYC (4/10/2026, 5:20:02 PM)

After market: 4.9 -0.04 (-0.81%)

4.94

-0.03 (-0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17
Earnings (Next)04-29
Inst Owners82.61%
Inst Owner Change0%
Ins Owners1.37%
Ins Owner Change5.75%
Market Cap342.68M
Revenue(TTM)72.59M
Net Income(TTM)-218.96M
Analysts80
Price Target13.17 (166.6%)
Short Float %4.6%
Short Ratio4.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.17%
Min EPS beat(2)22.68%
Max EPS beat(2)69.66%
EPS beat(4)2
Avg EPS beat(4)18.11%
Min EPS beat(4)-17.46%
Max EPS beat(4)69.66%
EPS beat(8)6
Avg EPS beat(8)21.05%
EPS beat(12)7
Avg EPS beat(12)12.09%
EPS beat(16)8
Avg EPS beat(16)6.74%
Revenue beat(2)2
Avg Revenue beat(2)310.76%
Min Revenue beat(2)56.87%
Max Revenue beat(2)564.66%
Revenue beat(4)3
Avg Revenue beat(4)145.01%
Min Revenue beat(4)-67.15%
Max Revenue beat(4)564.66%
Revenue beat(8)5
Avg Revenue beat(8)93.97%
Revenue beat(12)7
Avg Revenue beat(12)69.37%
Revenue beat(16)8
Avg Revenue beat(16)48.06%
PT rev (1m)-29.27%
PT rev (3m)-37.03%
EPS NQ rev (1m)29.15%
EPS NQ rev (3m)23.94%
EPS NY rev (1m)0%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)16.87%
Revenue NQ rev (3m)18.96%
Revenue NY rev (1m)11.8%
Revenue NY rev (3m)11.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.72
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-3.16
EYN/A
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-3.63
FCFYN/A
OCF(TTM)-3.6
OCFYN/A
SpS1.05
BVpS8.79
TBVpS8.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.51%
ROE -35.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.17%
ROA(5y)-23.98%
ROE(3y)-35.31%
ROE(5y)-33.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.59%
Cap/Sales 3.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.98
Quick Ratio 11.98
Altman-Z 0.18
F-Score2
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)32.85%
Cap/Depr(5y)151.43%
Cap/Sales(3y)5.87%
Cap/Sales(5y)33.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.63%
EPS Next Y-20.36%
EPS Next 2Y-5.36%
EPS Next 3Y6.12%
EPS Next 5Y15.79%
Revenue 1Y (TTM)105.77%
Revenue growth 3Y71.22%
Revenue growth 5Y47.52%
Sales Q2Q%1193.28%
Revenue Next Year5.39%
Revenue Next 2Y-14.06%
Revenue Next 3Y45.31%
Revenue Next 5Y77.32%
EBIT growth 1Y-18.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.57%
OCF growth 3YN/A
OCF growth 5YN/A

BICYCLE THERAPEUTICS PLC-ADR / BCYC Fundamental Analysis FAQ

What is the fundamental rating for BCYC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCYC.


Can you provide the valuation status for BICYCLE THERAPEUTICS PLC-ADR?

ChartMill assigns a valuation rating of 0 / 10 to BICYCLE THERAPEUTICS PLC-ADR (BCYC). This can be considered as Overvalued.


How profitable is BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?

BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a profitability rating of 1 / 10.


What is the expected EPS growth for BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?

The Earnings per Share (EPS) of BICYCLE THERAPEUTICS PLC-ADR (BCYC) is expected to decline by -20.36% in the next year.